These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 26070015)

  • 21. Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 May; 21(18):5568-74. PubMed ID: 25987781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of moxifloxacin in hospitalized patients with secondary peritonitis: pooled analysis of four randomized phase III trials.
    De Waele JJ; Tellado JM; Weiss G; Alder J; Kruesmann F; Arvis P; Hussain T; Solomkin JS
    Surg Infect (Larchmt); 2014 Oct; 15(5):567-75. PubMed ID: 24833256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Moxifloxacin plus standard first-line therapy in the treatment of pulmonary tuberculosis: A meta-analysis.
    Chen Z; Liang JQ; Wang JH; Feng SS; Zhang GY
    Tuberculosis (Edinb); 2015 Jul; 95(4):490-6. PubMed ID: 25964137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and tolerability of linezolid in children.
    Saiman L; Goldfarb J; Kaplan SA; Wible K; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
    Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S193-200. PubMed ID: 14520146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical experience with moxifloxacin in patients with respiratory tract infections.
    Faich GA; Morganroth J; Whitehouse AB; Brar JS; Arcuri P; Kowalsky SF; Haverstock DC; Celesk RA; Church DA
    Ann Pharmacother; 2004 May; 38(5):749-54. PubMed ID: 15026565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis.
    Vardakas KZ; Tansarli GS; Bliziotis IA; Falagas ME
    Int J Antimicrob Agents; 2013 Apr; 41(4):301-10. PubMed ID: 23410791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Moxifloxacin in complicated skin and skin structure infections (cSSSIs): A prospective, international, non-interventional, observational study.
    Bogner JR; Kutaiman A; Esguerra-Alcalen M; Heldner S; Arvis P
    Adv Ther; 2013 Jun; 30(6):630-43. PubMed ID: 23797470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single-agent, broad-spectrum fluoroquinolones for the outpatient treatment of low-risk febrile neutropenia.
    Cooper MR; Durand CR; Beaulac MT; Steinberg M
    Ann Pharmacother; 2011 Sep; 45(9):1094-102. PubMed ID: 21862714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective, randomized, study of ampicillin-sulbactam versus moxifloxacin monotherapy for the treatment of community-acquired complicated intra-abdominal infections.
    Chen CW; Ming CC; Ma CJ; Shan YS; Yeh YS; Wang JY
    Surg Infect (Larchmt); 2013 Aug; 14(4):389-96. PubMed ID: 23859673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
    Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
    Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
    Sacchidanand S; Penn RL; Embil JM; Campos ME; Curcio D; Ellis-Grosse E; Loh E; Rose G
    Int J Infect Dis; 2005 Sep; 9(5):251-61. PubMed ID: 16099700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delafloxacin in Acute Bacterial Skin and Skin Structure Infections.
    Corey GR; McKinnell JA; Rybak MJ
    Clin Infect Dis; 2019 Apr; 68(Suppl 3):S191-S192. PubMed ID: 30957163
    [No Abstract]   [Full Text] [Related]  

  • 33. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis.
    Starakis I; Gogos CA; Bassaris H
    Int J Antimicrob Agents; 2004 Feb; 23(2):129-37. PubMed ID: 15013037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Moxifloxacin vs amoxicillin/clavulanate in the treatment of acute sinusitis.
    Arrieta JR; Galgano AS; Sakano E; Fonseca X; Amábile-Cuevas CF; Hernández-Oliva G; Vivar R; González G; Torres A;
    Am J Otolaryngol; 2007; 28(2):78-82. PubMed ID: 17362810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical perspectives on new antimicrobials: focus on fluoroquinolones.
    Talan DA
    Clin Infect Dis; 2001 Mar; 32 Suppl 1():S64-71. PubMed ID: 11249831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections.
    Solomkin J; Zhao YP; Ma EL; Chen MJ; Hampel B;
    Int J Antimicrob Agents; 2009 Nov; 34(5):439-45. PubMed ID: 19692210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
    McDonald MB; Protzko EE; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL; Usner DW
    Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
    File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
    J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections.
    Parish LC; Routh HB; Miskin B; Fidelholtz J; Werschler P; Heyd A; Haverstock D; Church D
    Int J Clin Pract; 2000 Oct; 54(8):497-503. PubMed ID: 11198726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Omadacycline (Nuzyra)--a new tetracycline antibiotic.
    Med Lett Drugs Ther; 2019 May; 61(1572):74-77. PubMed ID: 31169800
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.